Novartis AG Files Q2 2024 Financial Report
Ticker: NVSEF · Form: 6-K · Filed: Jul 18, 2024 · CIK: 1114448
| Field | Detail |
|---|---|
| Company | Novartis Ag (NVSEF) |
| Form Type | 6-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-report, quarterly-results, sec-filing
TL;DR
Novartis dropped its Q2 2024 financials on 7/18 - check the reports for performance.
AI Summary
Novartis AG filed a Form 6-K on July 18, 2024, reporting its financial information as of June 30, 2024. The filing includes Exhibit 99.1, a Financial Report for Q2 2024, and Exhibit 99.2, an Interim Financial Report. Novartis AG is a pharmaceutical preparations company incorporated in V8 with its principal executive offices in Basel, Switzerland.
Why It Matters
This filing provides investors with the latest financial performance data for Novartis AG, crucial for assessing the company's current health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing by a large, established company and does not present immediate new risks.
Key Players & Entities
- Novartis AG (company) — Registrant
- July 18, 2024 (date) — Filing date
- June 30, 2024 (date) — Reporting period end date
- Basel, Switzerland (location) — Principal executive offices
- 2834 (industry_code) — Standard Industrial Classification
FAQ
What are the key exhibits included in this Form 6-K filing?
The key exhibits are 99.1 (Financial Report Q2 2024), 99.2 (Interim Financial Report), and 101 (Interactive Data).
What is the SEC file number for Novartis AG?
The SEC file number for Novartis AG is 001-15024.
When is the conforming period of report for this filing?
The conforming period of report is June 30, 2024.
What is the Standard Industrial Classification code for Novartis AG?
The Standard Industrial Classification code for Novartis AG is 2834 (Pharmaceutical Preparations).
Does Novartis AG file annual reports under Form 20-F or Form 40-F?
Novartis AG files annual reports under Form 20-F.
Filing Stats: 199 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2024-07-18 06:09:04
Filing Documents
- nvs-20240630.htm (6-K) — 9KB
- nvs-20240630-99_1.htm (EX-99) — 269KB
- nvs-20240630-99_2.htm (EX-99) — 2504KB
- letterheadpr.jpg (GRAPHIC) — 25KB
- logorm.jpg (GRAPHIC) — 29KB
- coverifr.jpg (GRAPHIC) — 123KB
- 0001370368-24-000019.txt ( ) — 12948KB
- nvs-20240630_cal.xml (EX-101.CAL) — 69KB
- nvs-20240630_def.xml (EX-101.DEF) — 471KB
- nvs-20240630_lab.xml (EX-101.LAB) — 1896KB
- nvs-20240630_pre.xml (EX-101.PRE) — 491KB
- nvs-20240630.xsd (EX-101.SCH) — 538KB
- nvs-20240630_htm.xml (XML) — 2302KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Novartis AG Date: July 18, 2024 By: /s/ PAUL PENEPENT Name: Paul Penepent Title: Head Financial Reporting and Accounting